Bayforest Capital Ltd Makes New $840,000 Investment in BioCryst Pharmaceuticals, Inc. $BCRX

Bayforest Capital Ltd bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 93,722 shares of the biotechnology company’s stock, valued at approximately $840,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Alkeon Capital Management LLC raised its holdings in shares of BioCryst Pharmaceuticals by 1.7% during the first quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company’s stock worth $54,105,000 after purchasing an additional 120,199 shares during the period. Millennium Management LLC raised its holdings in shares of BioCryst Pharmaceuticals by 382.6% during the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock worth $28,597,000 after purchasing an additional 3,022,769 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of BioCryst Pharmaceuticals by 25,631.2% during the second quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company’s stock worth $32,441,000 after purchasing an additional 3,606,566 shares during the period. Jupiter Asset Management Ltd. raised its holdings in shares of BioCryst Pharmaceuticals by 82.4% during the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company’s stock worth $16,117,000 after purchasing an additional 971,040 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 49.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock worth $14,490,000 after purchasing an additional 640,704 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 26th. Bank of America boosted their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, July 1st. Wedbush boosted their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an “outperform” rating in a research note on Monday, June 30th. Zacks Research raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $16.30.

BioCryst Pharmaceuticals Trading Down 2.5%

NASDAQ:BCRX opened at $7.04 on Tuesday. The company has a 50-day moving average of $7.98 and a 200-day moving average of $8.68. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of -39.11, a price-to-earnings-growth ratio of 1.45 and a beta of 1.05. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.01 and a twelve month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. The business’s revenue for the quarter was up 49.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.06) EPS. On average, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Insider Activity

In other news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the transaction, the director owned 65,352 shares of the company’s stock, valued at $556,145.52. The trade was a 51.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 5.10% of the stock is owned by corporate insiders.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.